165 related articles for article (PubMed ID: 29866864)
1. Linezolid Kills Acid-Phase and Nonreplicative-Persister-Phase Mycobacterium tuberculosis in a Hollow-Fiber Infection Model.
Drusano GL; Myrick J; Maynard M; Nole J; Duncanson B; Brown D; Schmidt S; Neely M; Scanga CA; Peloquin C; Louie A
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866864
[TBL] [Abstract][Full Text] [Related]
2. Activity of Moxifloxacin against
Louie A; Duncanson B; Myrick J; Maynard M; Nole J; Brown D; Schmidt S; Neely M; Scanga CA; Peloquin C; Drusano GL
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249693
[TBL] [Abstract][Full Text] [Related]
3. Effect of Linezolid plus Bedaquiline against Mycobacterium tuberculosis in Log Phase, Acid Phase, and Nonreplicating-Persister Phase in an
de Miranda Silva C; Hajihosseini A; Myrick J; Nole J; Louie A; Schmidt S; Drusano GL
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866874
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy.
Brown AN; Drusano GL; Adams JR; Rodriquez JL; Jambunathan K; Baluya DL; Brown DL; Kwara A; Mirsalis JC; Hafner R; Louie A
mBio; 2015 Nov; 6(6):e01741-15. PubMed ID: 26530386
[TBL] [Abstract][Full Text] [Related]
5. Effect of Moxifloxacin plus Pretomanid against
de Miranda Silva C; Hajihosseini A; Myrick J; Nole J; Louie A; Schmidt S; Drusano GL
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397058
[TBL] [Abstract][Full Text] [Related]
6. A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way.
Deshpande D; Srivastava S; Nuermberger E; Pasipanodya JG; Swaminathan S; Gumbo T
Clin Infect Dis; 2016 Nov; 63(suppl 3):S95-S101. PubMed ID: 27742640
[TBL] [Abstract][Full Text] [Related]
7. Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks.
Srivastava S; Deshpande D; Pasipanodya J; Nuermberger E; Swaminathan S; Gumbo T
Clin Infect Dis; 2016 Nov; 63(suppl 3):S102-S109. PubMed ID: 27742641
[TBL] [Abstract][Full Text] [Related]
8. The combination of rifampin plus moxifloxacin is synergistic for suppression of resistance but antagonistic for cell kill of Mycobacterium tuberculosis as determined in a hollow-fiber infection model.
Drusano GL; Sgambati N; Eichas A; Brown DL; Kulawy R; Louie A
mBio; 2010 Aug; 1(3):. PubMed ID: 20802826
[TBL] [Abstract][Full Text] [Related]
9. Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis.
Srivastava S; Modongo C; Siyambalapitiyage Dona CW; Pasipanodya JG; Deshpande D; Gumbo T
Antimicrob Agents Chemother; 2016 Oct; 60(10):5922-7. PubMed ID: 27458215
[TBL] [Abstract][Full Text] [Related]
10. Dose optimization of moxifloxacin and linezolid against tuberculosis using mathematical modeling and simulation.
Heinrichs MT; Drusano GL; Brown DL; Maynard MS; Sy SKB; Rand KH; Peloquin CA; Louie A; Derendorf H
Int J Antimicrob Agents; 2019 Mar; 53(3):275-283. PubMed ID: 30385322
[TBL] [Abstract][Full Text] [Related]
11. Mycobacterium tuberculosis sterilizing activity of faropenem, pyrazinamide and linezolid combination and failure to shorten the therapy duration.
Gumbo T; Sherman CM; Deshpande D; Alffenaar JW; Srivastava S
Int J Infect Dis; 2021 Mar; 104():680-684. PubMed ID: 33556616
[TBL] [Abstract][Full Text] [Related]
12. Linezolid for Infants and Toddlers With Disseminated Tuberculosis: First Steps.
Deshpande D; Srivastava S; Pasipanodya JG; Bush SJ; Nuermberger E; Swaminathan S; Gumbo T
Clin Infect Dis; 2016 Nov; 63(suppl 3):S80-S87. PubMed ID: 27742638
[TBL] [Abstract][Full Text] [Related]
13. The Funnel: a Screening Technique for Identifying Optimal Two-Drug Combination Chemotherapy Regimens.
Drusano GL; Kim S; Almoslem M; Schmidt S; D'Argenio DZ; Myrick J; Duncanson B; Nole J; Brown D; Peloquin CA; Neely M; Yamada W; Louie A
Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33199386
[TBL] [Abstract][Full Text] [Related]
14. Comparison of
Zong Z; Jing W; Shi J; Wen S; Zhang T; Huo F; Shang Y; Liang Q; Huang H; Pang Y
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29844043
[TBL] [Abstract][Full Text] [Related]
15. Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo.
Deshpande D; Srivastava S; Nuermberger E; Pasipanodya JG; Swaminathan S; Gumbo T
Clin Infect Dis; 2016 Nov; 63(suppl 3):S88-S94. PubMed ID: 27742639
[TBL] [Abstract][Full Text] [Related]
16. Activity of rifampicin and linezolid combination in Mycobacterium tuberculosis.
Maltempe FG; Caleffi-Ferracioli KR; do Amaral RCR; de Oliveira Demitto F; Siqueira VLD; de Lima Scodro RB; Hirata MH; Pavan FR; Cardoso RF
Tuberculosis (Edinb); 2017 May; 104():24-29. PubMed ID: 28454646
[TBL] [Abstract][Full Text] [Related]
17. Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis.
Wallis RS; Jakubiec W; Kumar V; Bedarida G; Silvia A; Paige D; Zhu T; Mitton-Fry M; Ladutko L; Campbell S; Miller PF
Antimicrob Agents Chemother; 2011 Feb; 55(2):567-74. PubMed ID: 21078950
[TBL] [Abstract][Full Text] [Related]
18. Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosis.
Drusano GL; Neely M; Van Guilder M; Schumitzky A; Brown D; Fikes S; Peloquin C; Louie A
PLoS One; 2014; 9(7):e101311. PubMed ID: 25003557
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis.
Rouan MC; Lounis N; Gevers T; Dillen L; Gilissen R; Raoof A; Andries K
Antimicrob Agents Chemother; 2012 Mar; 56(3):1444-51. PubMed ID: 22155815
[TBL] [Abstract][Full Text] [Related]
20. Does linezolid have a role in shortening treatment of tuberculosis?
Yew WW; Chan DP; Chang KC
Clin Microbiol Infect; 2019 Sep; 25(9):1060-1062. PubMed ID: 31238119
[No Abstract] [Full Text] [Related]
[Next] [New Search]
